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From GWAS to PheWAS: the search for causality in big data
Causal investigations in genetics have evolved from 
agnostic discovery in genome-wide association studies 
(GWAS) to functional annotation1 and instrumental 
variable-informed inference (ie, mendelian randomi-
sation)2. In the past decade, big data resources, 
such as the UK Biobank, have prompted a return to 
broader discovery through phenome-wide association 
studies (PheWAS).3 The work by Elina Hyppönen and 
colleagues4 in The Lancet Digital Health, joins a small 
body of studies5,6 using polygenic risk scores to search 
for causal effects of an intermediate phenotype 
such as body-mass index (BMI) on many outcomes, 
thereby applying mendelian randomisation across the 
phenome. 
The authors used UK Biobank data to construct a BMI 
genetic risk score based on genetic variants previously 
identified by the GIANT (Genetic Investigation of 
ANthropometric Traits) consortium. Using PheWAS 
followed by mendelian randomisation, Hyppönen 
and colleagues reproduced the effects of life-long, 
genetically-influenced changes in BMI on a range 
of disease outcomes. After Bonferroni correction, 
PheWAS identified possible associations between BMI 
genetic risk score and 58 outcomes, and 30 distinct 
disease associations were supported by follow-up 
mendelian randomisation analyses. For example, using 
inverse-variance weighted models, Hyppönen and 
colleagues found an increase in BMI to be associated 
with higher odds of endocrine disorders (odds ratio 
per unit increase in SD of higher BMI 2·72, 95% CI 
2·33–3·29, for type 2 diabetes; 2·11, 1·62–2·76, for type 
1 diabetes; and 1·46, 1·25–1·70, for hypothyroidism), 
circulatory diseases (1·96, 1·53–2·51, for phlebitis and 
thrombophlebitis; 1·89, 1·39–2·57, for cardiomegaly; 
1·68, 1·35–2·09, for congestive heart failure; 1·55, 
1·37–1·76, for hypertension; 1·31, 1·13–1·52, for 
ischaemic heart disease; and 1·25, 1·14–1·37, for cardiac 
dysrhythmias), and inflammatory or dermatological 
conditions (2·00, 1·72–2·23, for superficial cellulitis 
and abscess; 3·37, 2·17–5·25, for chronic ulcers of leg 
and foot; 4·99, 2·54–9·82, for gangrene; and 2·24, 
1·53–3·28, for atopy).
The work by Hyppönen and colleagues represents the 
state-of-the-art in applying a suite of complementary 
mendelian randomisation methods and adjustments 
for 40 principal components of polygenic risk scores to 
address population structure. Unlike a previous study,5 
Hyppönen and colleagues also restricted analyses 
to clinically-derived or registry-derived outcomes. 
Crucially, the authors draw attention to some of the 
more fundamental difficulties of causal discovery when 
applying this approach. Here, we review a few of these 
considerations, hoping that they will generate further 
dialogue. Notably, although challenges exist in using 
large databases for discovery,3,7 resilient confounding 
of polygenic risk scores,8 and causal interpretations 
of mendelian randomisation for lifelong traits,2 have 
been separately described, the extent of false causal 
discovery in their joint application is unknown.   
As noted by Hyppönen and colleagues4 and others,5 
false associations among UK Biobank participants 
might be induced by selection bias. Although 
corrections such as modelling selection probabilities7 
might be effective for single outcomes, whether similar 
strategies will be sufficient for PheWAS coupled to 
mendelian randomisation is not clear. The enrichment 
of false PheWAS hits have consequences on the 
number and composition of signals carried forward 
to mendelian randomisation analyses. For example, 
past longitudinal investigations9 have found reduced 
participation to be associated with BMI, smoking, and 
mental health polygenic risk scores. It follows that 
individuals with higher polygenic risk scores for BMI 
who choose to participate in the study might have 
lower risk of poor mental health than those who do 
not participate. This differential participation could 
explain counter-intuitive associations with reduced 
neuroticism observed previously5 or weaken the 
association with depression observed in this study.4 
Most concerningly, this finding implies that follow-up 
mendelian randomisation analyses can be enriched 
with confounded polygenic risk score–outcome 
associations, as the authors point out, violating the 
exclusion restriction assumption and invalidating false 
discovery rate control. 
As aptly described by Hyppönen and colleagues, 
specific assumptions about causal mechanisms 
are needed to estimate effects with mendelian 
randomisation (no horizontal pleiotropy, independ-
ence of pleiotropic effect sizes, and so on). In single 
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exposure-outcome mendelian randomisation, 
our belief that such assumptions are valid can be 
strengthened by triangulating substantive a priori 
knowledge, such as experimental findings and 
functional annotations. In PheWAS coupled to 
mendelian randomisation, the challenge of justifying 
independences is multiplied across all target outcomes. 
This is crucial because the strongest polygenic risk 
score–outcome associations in the first stage might 
be the most affected by pleiotropy and, conversely, 
weaker signals might be excluded even if they are 
causally valid. 
Additionally, a major strength of using genetic 
variation as so-called causal anchors in standalone 
PheWAS is that they are fixed at the time of zygote 
formation and thus, reverse causality is unlikely. 
However, as the authors point out, this clearly does 
not extend to BMI–phenotype associations, because 
pathophysiological development of an outcome can 
affect observed BMI. Although bidirectional mendelian 
randomisation can address this issue somewhat, they 
will only work when statistical power is high because a 
false negative (not identifying true reverse causation) 
due to low power will lead to increased confidence 
in a biased analysis. For conditions where there is a 
strong preceding suspicion of early onset, such as type 
1 diabetes or hypothyroidism, adult BMI will at least 
partly be determined by disease. In single-outcome 
studies, one could consider an appropriate latency 
period after BMI ascertainment and include only 
incident cases. Automating such a design in PheWAS 
would be challenging, because latency periods will 
differ between outcomes. 
The use of PheWAS coupled to mendelian 
randomisation on BMI associations is compelling 
because adiposity is affected by numerous outcomes 
during a lifetime and is subject to complex confounding 
and measurement errors. Crucially, conventional 
associations do not correspond to well defined causal 
effects because these will differ greatly depending on 
how, why, and in whom BMI is changed.10 Mendelian 
randomisation presents a potential way forward by 
providing necessary and sufficient conditions to isolate a 
particular causal effect—lifelong, genetically-influenced 
changes in BMI—that might operate similarly, 
on average, in all humans. However, in coupling 
mendelian randomisation with discovery (PheWAS), 
challenges are introduced that might undermine the 
clarity of any causal investigation. This comes from 
an inherent tension between structure-free discovery, 
where statistical inference relies solely on observed 
distributional characteristics, and causal inference, 
where validity rests on structural assumptions drawn 
from previous knowledge. The work by Hyppönen and 
colleagues represents the state-of-the-art in PheWAS 
coupled to mendelian randomisation, notably applying 
strict statistical corrections (ie, pleiotropy identification 
and multiple-testing corrections) to reduce false 
discovery. Importantly, their work highlights some 
broader challenges in balancing discovery and causation 
that go beyond PheWAS coupled to mendelian 
randomisation, noting how discovery approaches 
might amplify non-causal relationships and mask 
(statistically weaker) causal ones. Although the 
appropriate balance in PheWAS coupled to mendelian 
randomisation remains an open question, it is certain 
that greater consideration for biological function is 
needed, including—as the authors suggest—a priori 
negative control outcomes (unlikely to be affected by 
BMI) and formal use of functional annotations1 in the 
development of polygenic risk scores to improve the 
likelihood of causal discoveries. Ultimately, any causal 
discovery approach will be successful to the degree 
that all discoveries are subject to the same careful 
consideration as single exposure-outcome studies.   
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